289 Frequency and acceptance of CDSS-generated STOPP/START signals Table 2. Continued. Top 10 most frequently generated STOPP signals Frequency, N Acceptance, % START A5 – Statin therapy with a documented history of coronary, cerebral or peripheral vascular disease, unless the patient’s status is end-of-life or age is > 85 years. 80 62.5% START G2 – 5-alpha reductase inhibitor with symptomatic prostatism, where prostatectomy is not considered necessary. 79 15.2% START D2 – Fibre supplements for diverticulosis with a history of constipation. 76 18.4% START A1A2 – VKA or direct thrombin inhibitors or factor Xa inhibitors in the presence of chronic atrial fibrillation. If an oral anticoagulant is contraindicated, start aspirin (75-160 mg) instead. 72 50.0% Other START criteria 571 29.4% START signals that were never generated START C4 - Topical prostaglandin, prostamide or beta-blocker for primary open-angle glaucoma. 0 N/A START G3. Topical vaginal oestrogen or vaginal oestrogen pessary for symptomatic atrophic vaginitis. 0 N/A Total 1615 37.2% Detailed information on frequency and acceptance for all STOPP/START signals – in total and per country – can be found in Supplementary Information SI1. Note: some of the original STOPP/START criteria v2 titles are shortened. VKA = vitamin K antagonist; NSAID = non-steroid anti-inflammatory drug; SSRI = selective serotonin reuptake inhibitors; ACE-I = Angiotensin-converting enzyme inhibitors; PPI = Proton-pump inhibitor; PRN = pro re nata (as needed); eGFR = estimated glomerular filtration rate. ART i l 4
RkJQdWJsaXNoZXIy MTk4NDMw